Skip to content Skip to footer

Eli Lilly Licenses Camurus’ FluidCrystal Technology to Advance Long-Acting Incretin Products

Shots:

  • Camurus has granted Eli Lilly exclusive global rights to research, develop, manufacture, & commercialize long-acting incretin drugs using Camurus’ FluidCrystal tech for cardiometabolic diseases 
  • As per the deal, Camurus will receive ~$290M in upfront, development & regulatory milestones as well as $580M in sales-based milestones & global net sales-based tiered royalties in mid-single digits
  • Agreement incl. up to 4 Lilly proprietary drugs, selected from dual GIP & GLP-1 receptor agonists, triple GIP, glucagon & GLP-1 receptors agonist, with an option to incl. amylin receptor agonists

Ref: PRNewswire | Image: Eli Lilly and Camurus | Press Release

Related News:- Rznomics Partners with Eli Lilly for RNA Editing Therapeutics

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]